Downregulation of miR-146b-5p via iodine involvement repressed papillary thyroid carcinoma cell proliferation

Pan, Yujia; Yun, Weikang; Shi, Bingshuai; Cui, Rongjun; Liu, Chi; Zhong, Di; Fan, Jialin; Jiang, Wenqian; Tang, Jingling; Zheng, Tianyue; Yu, Xiuchong; Liu, Ying

doi:10.1530/jme-19-0198

Cited by 7 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have shown that miR-146b is related to the occurrence, development, proliferation, invasion, and metastasis of thyroid cancer (19)(20)(21). Several reports have confirmed miR-146b to be highly expressed in patients with a high risk of BRAF V600E mutations and advanced PTC (P = 0.001), suggesting that miR-146b is a marker of recurrence or metastasis in PTC patients (20).…”

Section: Discussionmentioning

confidence: 99%

Downregulation of miR-146b-3p Inhibits Proliferation and Migration and Modulates the Expression and Location of Sodium/Iodide Symporter in Dedifferentiated Thyroid Cancer by Potentially Targeting MUC20

et al. 2021

View full text Add to dashboard Cite

The dedifferentiation of differentiated thyroid cancer (DTC) is a challenging problem for radioactive iodine (131I) treatment, also known as radioiodine refractory differentiated thyroid cancer (RAIR-DTC). The purpose of this study was to further explore the mechanism of the redifferentiation of dedifferentiated thyroid cancer. Ineffective and effective groups of 131I therapy were analyzed and compared in both our clinical and TCGA samples. Whole-exome sequencing, mutation analysis, transcriptome analysis, and in vitro functional experiments were conducted. FLG, FRG1, MUC6, MUC20, and PRUNE2 were overlapping mutation genes between our clinical cases, and the TCGA cases only appeared in the ineffective group. The expression of miR-146b-3p target MUC20 was explored. The expression levels of miR-146b-3p and MUC20 were significantly increased, and the inhibition of miR-146b-3p expression significantly inhibited proliferation and migration, promoted apoptosis, regulated the expression and location of thyroid differentiation-related genes, and sodium/iodide symporter (NIS) in dedifferentiated thyroid cancer cells (WRO). Thus, miR-146b-3p potentially targets MUC20 participation in the formation of DTC dedifferentiation, resulting in resistance to 131I and the loss of the iodine uptake ability of DTC cancer foci, promoting refractory differentiated thyroid cancer. miR-146b-3p may be a potentially therapeutic target for the reapplication of 131I therapy in dedifferentiated thyroid cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Downregulation of miR-146b-3p Inhibits Proliferation and Migration and Modulates the Expression and Location of Sodium/Iodide Symporter in Dedifferentiated Thyroid Cancer by Potentially Targeting MUC20

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Furthermore, overexpression of miR-146b-5p promoted the proliferation, migration, and invasion of HT29 and SW620 cells, while its inhibition suppressed the proliferation, migration, and invasion of CRC cells. miR-146b-5p is expressed in most human organs and serves important roles in numerous diseases, including neurodegenerative diseases (33,34), inflammation (35)(36)(37) and tumors (38,39). Wu et al (34) identified differentially expressed miRNAs in peripheral blood of patients with Alzheimer's disease using small RNA sequencing and reported that miR-146b-5p might contribute to this disease.…”

Section: Discussionmentioning

confidence: 99%

miR‑146b‑5p promotes colorectal cancer progression by targeting TRAF6

Shi

Zheng

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

Increasing evidence highlights the multiple roles of microRNAs (miRs) in the tumorigenesis of colorectal cancer (CRC); however, the molecular mechanism, particularly the target of miR-146b-5p in CRC has not been fully elucidated. The present study aimed to elucidate the influence of miR-146b-5p via regulating tumor necrosis factor receptor-associated factor 6 (TRAF6) in CRC. The expression levels of miR-146b-5p and TRAF6 in CRC tissue and cells were determined by reverse transcription quantitative PCR and western blotting. Binding between miR-146b-5p and TRAF6 was examined using a dual luciferase reporter gene assay. The impact of miR-146b-5p and TRAF6 on proliferation and migration of CRC cells was determined using Cell Counting Kit-8 and Transwell assays, respectively. An animal model of CRC was established to determine the carcinogenic effect of the miR-146b-5p-TRAF6 axis. The results demonstrated that miR-146b-5p was highly expressed in CRC tissue samples compared with in normal adjacent tissue samples and in CRC cells compared with in the normal NCM460 cell line, whereas TRAF6 was expressed at low levels. Overexpression of miR-146b-5p decreased TRAF6 expression in CRC HT29 and SW620 cells. miR-146b-5p targeted and inhibited TRAF6 expression in CRC cells. Furthermore, transfection with a miR-146b-5p mimic promoted the proliferation, migration and invasion of CRC cells and tumor growth; however, these effects were abolished by TRAF6 overexpression. Transfection with a miR-146b-5p inhibitor suppressed the proliferation of CRC cells. Taken together, the results from the present study demonstrated that miR-146b-5p could enhance the initiation and tumorigenesis of CRC by targeting TRAF6. These results will help elucidate the mechanisms underlying CRC development and will facilitate the development of targeted therapy for CRC.

show abstract

“…Several studies have shown that transforming growth factor (TGF)-b1 regulates specific miRNAs, such as mir-146b-5p, in normal cells and cancer. Because TGF-b1 also regulates epithelial-mesenchymal transition in PTC, this growth factor has important roles in the expression of specific miRNAs for the progression of thyroid cancer (30)(31)(32). Inactivating miR-146b has been considered as a promising strategy also in thyroid cancer therapy.…”

Section: Discussionmentioning

confidence: 99%

Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling

et al. 2022

View full text Add to dashboard Cite

Papillary thyroid carcinoma (PTC) is a miscellaneous disease with a variety of histological variants, each with its own mutational profile, and clinical and prognostic characteristics. Identification of microRNA (miRNA) expression profiles represents an important benchmark for understanding the molecular mechanisms underlying the biological behavior of these unique PTC subtypes in order that they be better characterized. We considered a series of 35 PTC samples with a histological diagnosis of either hobnail (17 cases) or classical variant (nine cases) and with a specific BRAF p.K601E mutation (nine cases). We determined the overall miRNA expression profile with NanoString technology, and both quantitative reverse transcription–PCR and in situ hybridization were used to confirm selected miRNAs. The miRNA signature was found to consistently differentiate specific histotypes and mutational profiles. In contrast to the BRAF p.K601E mutation and classic PTCs, three miRNAs (miR-21-5p, miR-146b-5p, and miR-205-5p) were substantially overexpressed in the hobnail variant. The current study found that different miRNA signature profiles were linked to unique histological variants and BRAF mutations in PTC. Further studies focusing on the downstream pathogenetic functions of mRNAs in thyroid neoplasms are warranted.

show abstract

Downregulation of miR-146b-5p via iodine involvement repressed papillary thyroid carcinoma cell proliferation

Cited by 7 publications

References 24 publications

Downregulation of miR-146b-3p Inhibits Proliferation and Migration and Modulates the Expression and Location of Sodium/Iodide Symporter in Dedifferentiated Thyroid Cancer by Potentially Targeting MUC20

Downregulation of miR-146b-3p Inhibits Proliferation and Migration and Modulates the Expression and Location of Sodium/Iodide Symporter in Dedifferentiated Thyroid Cancer by Potentially Targeting MUC20

miR‑146b‑5p promotes colorectal cancer progression by targeting TRAF6

Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling

Contact Info

Product

Resources

About